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I.

Introduction

Insulin and aldosterone have long teen recognized to
play important roles in potassium homeostasis.

Both have

been shown to participate in feed-back control circuits
whereby rises in the plasma potassium concentration stim¬
ulates the release of each hormone (1,33).
levels of plasma aldosterone,

in turn,

Increased

stimulates both

the renal excretion (33-36) and the extrarenal cellular
uptake (34,38) of potassium.

The primary influence of

insulin on potassium balance is to augment extrarenal
uptake of potassium, predominantly by liver and skeletal
muscle (4-,6-11).

Recent studies have suggested that epi¬

nephrine and other sympathomimetic substances may also play
an important role in maintaining potassium homeostasis (2,
51).

More specifically, beta-adrenergic agonist agents have

been shown to ameliorate the rise in serum potassium concen¬
tration following the administration of potassium chloride in
cats (2,49).

However, "whether such a protective effect

exists in man and the mechanisms underlying this effect have
not been completely studied.

It is the purpose of the pres¬

ent thesis to examine whether catecholamines exert a protec¬
tive effect against hyperkalemia

in man and to define the

mechanism or mechanisms by which such an effect might occur.
Attention will also be given to the possible interrelation-

ships between the protective effect of catecholamines on
potassium tolerance and the previously described insulin
and aldosterone feed-back systems.
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II.

A.

Overview

Insulin and Potassium
Insulin infusion has long been known to lower the

serum potassium concentration (3).

This effect is thought

to he mediated by promoting the transfer of extracellular
potassium into ceils, particularly liver and skeletal muscle
(4,6-11).

Andres and coworkers (10)

employing the forearm

perfusion technique in human subjects were among the first to
demonstrate that insulin stimulated skeletal muscle uptake of
potassium.

Furthermore, the insulin mediated stimulation of

potassium uptake occurred at levels of insulin that had no
effect on muscle uptake of glucose.
did move to enhance potassium uptake.

Glucose uptake, however,
In addition,

Zierler

(6-8) and others (9) have found that incubation of muscle tis¬
sue in vitro with insulin causes intercellular accumulation
of potassium and hyperpolarization of the cell membranes even
In the absence of glucose in the incubation medium.

The mole¬

cular mechanism of this action of insulin has not been com¬
pletely elucidated but it has been postulated that this effect
of insulin on potassium is part of the chain of events which
results in cellular uptake of glucose (6,8).

Insulin-mediated

uptake by liver cells has been less well defined.
studies by Penn et al.

(3)

Early

suggested that the liver disposed

of potassium following insulin administration.

More recently,
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DeFronzo and coworkers,

employing hepatic venous catheteri¬

zation in combination with the insulin clamp technique, have
shown that over half of the potassium disappearing from the
extracellular space following insulin administration can be
accounted for by hepatic uptake (12).

An effect of insulin

on potassium uptake by the brain has also been demonstrated
(13) but this is small compared to the muscle and liver
uptake.
The clinical importance of insulin in maintaining
potassium homeostasis is particularly evident in diabetic
subjects.

When these patients are given an exogenous glu¬

cose infusion creating a

state of hyperglycemia, no change

or a slight rise in serum potassium occurs (ll).

This is

in contrast to normal subjects in whom hyperglycemia leads
to a decline in serum potassium concentration through elicit¬
ing secretion of insulin (ll).

It has been postulated that

hyperglycemia causes the osmotic extraction of fluid and
electrolytes (predominantly potassium) from the intercellular
environment (13)-

Glucose induced insulin release is respons¬

ible for the transport of potassium back into cells.

In dia¬

betics who lack both insulin and the second important potas¬
sium regulatory hormone aldosterone, hyperglycemia may thus
result in lethal hyperkalemia

(11,14,15).

While changes in the circulating insulin levels may
effect serum potassium concentrations,

it has also been dis¬

covered that basal insulin levels play a role in potassium
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homeostasis.

DeRronzo and coworkers (15,16) have shown that

in normal subjects and maturity-onset diabetics who retain
the ability to secrete insulin, the inhibition of basal
insulin secretion with somatostatin results in a

significant

rise in serum potassium concentration of 0.5 to 0.6 mEq/1
without a change in urinary potassium excretion.
a

In contrast,

similar administration of somatostatin to Juvenile-onset

diabetics who lack endogenous insulin release has no effect
on serum potassium concentration.

Replacement of basal

insulin levels by continuous insulin infusion in the control
group reversed the somatostatin induced rise in serum potas¬
sium.

Somatostatin has also been shown to markedly impair

the ability of dogs to dispose of an acutely administered
potassium load (16).

Again, replacement of basal insulin

levels restored potassium tolerance to normal.

Thus, main¬

tenance of basal insulin levels plays an important role in
the defense against hyperkalemia.
In order to complete the circuit of a proposed insulinpotassium feedback loop,

it is necessary to show that potas¬

sium is capable of stimulating the release of insulin.

Such

an effect has been demonstrated in the isolated, perfused
rat (17) and dog (18) pancreas, and following potassium infu¬
sion in the dog (19) and in man (20).

However,

in most of

these studies, the increment in plasma potassium concentration
necessary to stimulate insulin release was in excess of 1.5 to
2.0 mEq/1.

In studies where the plasma potassium concentration

6
was raised by less than 1.5 to 2.0 mEq/1, it has been dif¬
ficult to demonstrate an increase in circulating insulin
levels.

Thus, Sterns et al.

(21) found no change in plasma

insulin levels during a potassium infusion which raised the
plasma potassium concentration by a mean of 1.15 mEq/1, and
Dluhy and coworkers (20) likewise failed to observe a rise in
plasma insulin concentrations in response to an infusion of
potassium which raised the serum potassium concentration by
1.5 to 2.0 mEq/1.

Complicating the interpretation of these

data is the fact that the portal vein insulin concentration
may be four to five times the measured peripheral insulin
concentration (22).

It is thus possible that even small

increments in plasma potassium concentration may result in
significant insulin secretion which, because of the large
extraction of insulin by the liver would not be reflected in
the periphery.

Such unmeasured insulin could still be active

in effecting potassium metabolism in the liver.

Support for

this thesis comes from the work of Bleckard et al. who found
a significant rise in the portal vein

insulin concentration

following potassium chloride administration without a change
in peripheral insulin levels (22).

Since recent studies by

DeFronzo and coworkers (12) have shown the liver to be an
important site of insulin mediated potassium uptake, local
increases in portal vein insulin concentrations may play an
important role in potassium homeostasis.

However, even in the

absence of a rise in plasma insulin concentration levels, the

maintenance of basal insulin levels has been shown to play
an important role in potassium homeostasis.
Insulin has also been related to potassium excretion
in studies by DePronzo et al.

(23) who showed that physio¬

logic hyperinsulinemia is associated with a decline in the
rate of urinary potassium excretion.

However, this seemed

to be secondary to a fall in plasma, and thus filtered,
potassium concentration.

A direct effect of insulin of

renal tubular handling of potassium was not demonstrable in
studies with dogs.
B. Aldosterone and Potassium
Aldosterone is an adrenal steroid hormone which medi¬
ates the exchange of sodium and potassium in the distal renal
tubule.

Though many factors influence aldosterone secretion,

potassium is known to be a potent aldosterone secretagogue.
Potassium has been found by McCaa

et al.

(24) to be a more

potent aldosterone secretagogue than angiotensin II in dogs
chronically administered either potassium or angiotensin II.
This stimulatory effect has also been shown in isolated rat
and human (25) adrenal cortical cells incubated in vitro
with potassium,

in isolated adrenal glands perfused with

potassium and in intact dogs (24,26,27), and in man (28) per¬
fused with potassium.

Bluhy and coworkers have demonstrated

the release of aldosterone in man without an increment in
serum potassium during potassium infusion (28).

This effect
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■was observed in nephrectomized and hypophysectomized animals
thereby eliminating renin and ACTH as primary stimuli to
aldosterone secretion.

Infusion of potassium into adrenal

arteries resulted in aldosterone release without a rise in
peripheral potassium concentration indicating again that
potassium is a direct aldosterone secretogogue.
site direction,

In the oppo¬

infusion of glucose or insulin which lowers

the serum potassium concentration by as little as 0.3 mEq/1
has been shown to decrease aldosterone levels by fifty per
cent (28).

These data indicate that physiologic decreases

as well as increases in potassium concentration are important
regulators of aldosterone secretion.

These effects of potas¬

sium have been shown to be independent of dietary sodium
intake and to occur in anephric patients (l).
In addition to its effect on aldosterone release, potas¬
sium has also been shown to exert a
aldosterone synthesis.

stimulatory effect on

Potassium increases the activity of

the 18-hydroxylase enzyme which catalyzes the penultimate
step in aldosterone synthesis (29).

This effect has been

demonstrated in cultured zona glomerulosa adrenal cells (29).
In human subjects, with the terminal part of the aldosterone
synthesis pathway isolated with metyrapone (30), a requirement
for potassium has been found with the initial step in aldos¬
terone synthesis as well.
Kaplan et al.

(31).

This confirms earlier work by
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More recently,

Catt (32) lias shown that potassium

also plays a permissive role for other aldosterone secretagogues.

Using isolated zona glomerulosa cells he demon¬

strated that a decrease in the incubation potassium concen¬
tration markedly inhibits the activity of angiotensin and
ACTH to stimulate aldosterone release.
The importance of aldosterone in maintaining normal
potassium homeostasis has been recognized for years.
terone deficiency is known to result in hyperkalemia

Aldos¬
(33)

while aldosterone excess is associated with hypokalemia

(3^)«

In contrast to insulin, which exerts its major effect on
extrarenal potassium handling, aldosterone acts primarily by
augmenting renal potassium excretion (35?36).

Thus, in ani¬

mals the ability of the distal nephron to excrete potassium is
markedly impaired, and acute and chronic potassium tolerance
is diminished,

in the absence of aldosterone.

Some evidence does exist, however, that aldosterone
may play a small role in extrarenal potassium homeostasis as
well.

Alexander and Levinsky (37) found that nephrectomized

rams on a high potassium diet had a better potassium toler¬
ance following an acute potassium load than those kept on a
normal potassium diet.

Their results indicate that an extra¬

renal effect of aldosterone on potassium handling exists that
is dependent on a

state of chronic hyperaldosteronism second¬

ary to a high potassium diet.

A possible cellular mechanism

for this effect comes from the work of Adler (38) who found
that aldosterone enhances potassium uptake by skeletal muscle

cells in vitro, and that this enhancement is greater at
elevated concentrations of potassium (7-5 mEq/l) in the
incubation medium.
In summary,

elevation of the serum potassium concen¬

tration results in increased synthesis and release of
aldosterone which in turn enhances both renal and extra
renal potassium disposal.
C.

Epinephrine and Potassium
D'Silva was the first to suggest that epinephrine

might play a role in potassium homeostasis (39)-

He found

that an intravenous infusion of epinephrine into anesthetized
cats resulted in a triphasic response in the plasma potassium
concentration.

Within the first two minutes following epi¬

nephrine administration, there was a
potassium concentration.

small rise in the plasma

This was followed by a decrease in

the concentration to levels 1 mEq/l below the baseline value
by ten minutes following epinephrine administration.

Subse¬

quently, the plasma potassium concentration slowly returned
to baseline over the nexh thirty minutes.

This effect of

epinephrine was mimicked by the sympathomimetic agent ephedrine and abolished by ergotamine, a

sympatholytic agent.

The triphasic response of plasma potassium concentration to
epinephrine infusion has been observed many times since this
first report (40).
Employing hepatic catheterization in cats, D'Silva
further found that the liver was the sire of the potassium
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release responsible for the initial rise in the potassium
concentration following epinephrine administration (41).
Eepatectomy abolished the early hyperkalemic effect of epi¬
nephrine completely.

D*Silva,

and subsequently Brewer (42),

have shown by the same technique that the second phase
decline in plasma potassium concentration following epineph¬
rine infusion is largely the result of hepatic sequestration
of potassium (4,43,44).
An extrahepatic effect of epinephrine on potassium
homeostasis has been suggested in the work of several inves¬
tigators showing an effect of epinephrine on skeletal muscle
potassium uptake (44,45).

Epinephrine infusion into the

femoral artery of dogs enhances the arterial-venous plasma
potassium concentration difference indicating that peripheral
uptake of potassium has occurred.

That this increased uptake

is probably accounted for by muscle tissue is suggested by
studies in cats (2) and frogs (45) demonstrating increased
potassium content of skeletal muscle following epinephrine
induced hypokalemia.
The mechanism of the initial hyperkalemic effect of
epinephrine has been shown by Vick and coworkers (46,47) to
be mediated by alpha adrenergic receptors.
hypokalemia, conversely,
receptor stimulation.

The subsequent:

is shown to be due to beta-adrenergic

Pre-treatment with the specific alpha

agonist phenoxybenzamine inhibited the initial rise and aug¬
mented the subsequent fall in plasma potassium concentration
following epinephrine administration indicating that the
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alpha agonistic effects of epinephrine are predominantly
hyperkalemic.

When phenoxybenzamine -was administered alone,

a decline in the potassium concentration ensued indicating a
role for basal alpha
stasis (47).

sympathetic activity in potassium homeo¬

Infusion of the specific a3.pha agonist phen¬

ylephrine caused a rise in the plasma potassium concentration
supporting these results.

Pretreatment with the specific beta

sympathetic agonist propranolol prevented the secondary fall
in the potassium level following epinephrine administration,
indicating that beta receptor stimulation is responsible for
the hypokalemic phase of the epinephrine response.

This find¬

ing is supported by the observation that isoproterenol, a pure
beta

stimulant, causes a fall in the plasma potassium concen¬

tration to a greater extent than with epinephrine.

Interest¬

ingly, changes in the potassium concentration following the
infusion of isoproterenol and phenylephrine followed closely
those with epinephrine administration,
alpha and beta activity (48).

finally,

confirming its mixed
in limited studies in

man, propranolol was found to block the hypokalemic effect of
a 10 ug/min epinephrine infusion (48).
In summary, the effect of epinephrine on potassium
metabolism results from combined alpha and beta adrenergic
stimulation with the alpha
and the beta

effect later.

effect predominating initially
The initial hyperkalemic effect

is mediated via hepatic potassium release while both skeletal
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muscle and liver uptake of potassium play a role in the sub¬
sequent hypokalemic effect.
The protective effect of beta

stimulation on potassium

tolerance has been further studied by Lum and Lockwood (2,
4-9).

In cats infused with potassium to the point of fatal

cardiac toxicity,

epinephrine was found to ameliorate the

rise in plasma potassium concentration and increase survival.
The specific beta-2 agonists soterenol and salbutamol mimicked
this protective effect but the specific beta-1 stimulant
l-isopropyl-2-(2-thiazoxy)-2 propanol did not.

Similarly,

the specific beta-2 antagonist butoxamine abolished the pro¬
tective effect of epinephrine while the specific beta-1
antagonist practolol did not.

Thus, the beta-2 adrenergic

receptor appears to be the mediator of the hypokalemic effects
of epinephrine.

Interestingly,

in Lum and Lockwood's work,

the protective effect of epinephrine in acutely induced hyper¬
kalemia persisted in pancreatectomized animals,

excluding any

role for insulin.
finally, there is evidence that epinephrine infusion
causes changes in renal potassium metabolism.
to its effect on the systemic circulation,

In contrast

epinephrine causes

an increase in renal vascular resistance and a concomitant
reduction in renal blood flow (50).

Renin secretion is also

enhanced by epinephrine and would be expecred to increase
potassium excretion by the kidney.

The changes in renal hemo¬

dynamics have been shown by Smythe et al.

(51) to be associated
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with a marked decrease in potassium excretion without any
change in glomerular filtration rate by an as yet unclear
mechanism.
D.

Epinephrine and Insulin
Epinephrine has been shown to inhibit insulin secre¬

tion in a variety of experimental systems:

isolated perfused

pancreas (52) and in intact man and animals (53-55)•

Porteet

al. (54,55) showed that infusion of epinephrine into human
subjects resulted in hyperglycemia (ISO mg/dl) yet no increase
in serum immunoreactive insulin (IPE) occurred.

A similar

degree of hyperglycemia following glucose infusion without
epinephrine resulted in an immediate and significant increase
in serum insulin levels.

When the epinephrine infusion was

stopped in the former study, an abrupt increase in the insulin
level to three-fold above basal ensued.

Porte also showed

that epinephrine inhibited the rise in serum insulin concen¬
tration following glucose, glucagon and tolbutamide adminis¬
tration.

Infusion of phentolamine, an alpha adrenergic block¬

ing agent, reversed the inhibitory effect of epinephrine and
the insulin concentration role (56).

In contrast, isopro¬

terenol, a beta adrenergic agonist, was found to stimulate
insulin release.

These observations indicate that the effect

of alpha adrenergic stimulation is to inhibit insulin release
while beta adrenergic stimulation results in insulin secre¬
tion.

■

The effect of epinephrine on insulin secretion has been
further defined with more frequent sampling and prolongation
of epinephrine infusion in human subjects (56,57)-

An initial

fall in serum insulin levels occurred during the first fif¬
teen minutes of epinephrine infusion and this was followed
by a gradual rise to baseline by sixty minutes, and to levels
two-fold above basal at one hundred and twenty minutes.
initial decline was reversed by phentclamine,
quent recovery, by propranolol.

The

and the subse¬

A similar effect has been

reported in the isolated perfused dog pancreas (52).
Finally, the effect of endogenous sympathetic activity
on basal insulin secretion has been investigated by the infu¬
sion of phentolamine or propranolol alone.

Phentolamine led

to an increase in the serum insulin levels whereas propranolol
resulted in a fall (58).

Neither infusion had an effect on

the serum glucose concentration.
Thus, as with epinephrine and potassium, the relation¬
ship between epinephrine and insulin seems to be dependent on
a balance between alpha and beta adrenergic mechanisms.

The

predominant effect of epinephrine at the rate of infusion
used in most studies (6jig/min) is an inhibition of insulin
release which is mediated through alpha adrenergic receptors;
an increase in insulin secretion is observed following beta
adrenergic stimulation.

A similar effect of epinephrine has

also been documented with more physiologic doses of epineph¬
rine (20-60jig/min) in human subjects (58).
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E.

Epinephrine and Aldosterone
Sympathetic stimulation is one of the recognized fac¬

tors which stimulates renin secretion from the kidney and
thus,

indirectly, aldosterone release from the adrenal cor¬

tex (59).

A direct effect of epinephrine on aldosterone

synthesis or release has not been described.
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III.

Purpose

The present study seeks to define the role of epineph¬
rine in potassium homeostasis in human teings.

Previous

studies have largely dealt with epinephrine induced changes
in plasma potassium concentration in anesthetized laboratory
animals and have employed pharmacological doses of epineph¬
rine, resulting in serum epinephrine levels even above those
found in conditions of stress.

In studies involving potas¬

sium infusion in conjunction with epinephrine infusion to
test epinephrine's effect on potassium tolerance, the dose
of potassium chloride employed was also pharmacologic with
resulting plasma potassium concentrations in the 8 to 10
mEq/1 range, and cardiac toxicity and death employed as the
endpoint.

Whether epinephrine plays a protective role in

ameliorating rises in plasma potassium concentration within
the physiologic range has not been examined.

In addition,

no studies have been performed in which changes in renal
handling of potassium were measured and correlated with
changes in plasma potassium concentration during epinephrine
or epinephrine and potassium chloride infusion.

Similarly,

the influence of epinephrine on insulin and aldosterone,
hormones known to effect potassium homeostasis, was never
evaluated in these previous studies.

Finally, the effect

of changes in plasma potassium concentration on catecholamine
secretion has not previously teen defined.

It is to these

questions that the present study is addressed.
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IV.
A„

Methods

Subjects
Six healthy volunteers were obtained ranging in age

from 18 to 22 years (mean 19-5 - 0.7 yr).
(Table I).

There were 5 males and 1 female,

ho sub¬

ject had any significant past medical illness, none was
taking any medications, and all were consuming a diet con¬
taining at least 200 grams of carbohydrate per day for three
days prior to study.
diabetes mellitus.

One patient had a family history of
Informed, written consent was obtained

from each subject prior to their participation in the study.
B.

Experimental Protocol
All studies were performed in the postabsorptive state

at 8 a.m. following a 12 hour overnight fast.

All subjects

remained recumbent during the study except to void.

Prior

to study, polyethylene catheters were inserted under local
xylocaine anesthesia into an antecubital vein for blood samp¬
ling and into a femoral vein for the infusion of all test
substances.

All subjects were given a distilled water load

(15 ml/kg) followed by enough distilled water orally to
ensure voiding every 30 minutes.

Following the collection

of two to three baseline urine samples, the infusion of test
substances was begun.

Each subject participated in three

sequential studies and thereby served as his own control.
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In the first study (Figure l), potassium chloride
(Potassium Chloride Injection, IVNEX Pharmaceuticals,
Chagrin Falls, Ohio) was infused via a constant infusion
pump (Model 979 Compact Infusion Pump, Harvard Apparatus,
Millis, Mass.) at a rate of 0.75 mEq/kg over two hours.

The

potassium chloride was dissolved in half-normal saline solu¬
tion and infused at the rate of 0.74 ml/min.

The study was

continued for an additional two hours after stopping the
potassium infusion.

In the second study, subjects received

the same potassium chloride infusion as in the first study.
In addition, a constant infusion of epinephrine chloride
(Adrenalin Chloride Solution 1:1000, Parke-Davis and Co.,
Detroit, Mich.) at the rate of 0.05 pig/kg/min was started

30 minutes prior to beginning the potassium infusion and was
continued throughout the four hour study period.

The epi¬

nephrine was dissolved in half-normal saline and was admin¬
istered at the rate of 0.27 ml/min.

In the third study, potas¬

sium chloride and epinephrine were administered as above.
addition, a constant infusion of propranolol hydrochloride
(Inderal, Ayerst Laboratories, Inc., New York. N.Y.) given
at the rate of 1.43 pig/kg/min was begun concomitantly with
the epinephrine.

The propranolol was dissolved in half-

ncrmal saline and infused at the rate of 0.27 ml/min.
Blood pressure, heart rate and electrocardiogram were
monitored at 15-30 minute intervals throughout each study.

In
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Following at least two baseline samples, blood samples
were drawn at 15-30 minute intervals throughout the study and
analyzed for potassium,
creatinine,

sodium, glucose,

insulin, aldosterone,

epinephrine and norepinephrine.

ml of blood was drawn per study.

A total of 400

The sum of infused solutions

including normal saline to flush the blood drawing catheter
was also approximately 400 ml.
Urine samples were collected at 30 minute intervals
during the study and were analyzed for potassium,

sodium and

creatinine.
C.

Analytical Determinations
Potassium and sodium concentrations in plasma and urine

were determined by flame spectrophotometry (Flame Photometer
Model 143, Instrumentation Laboratory, Lexington, Mass.)
using lithium as the internal standard.

Plasma and urine

creatinine concentrations were determined by the method of
Jaffe adapted to the Auto Analyzer (60).

Methods for the

determination of plasma insulin (61) and plasma aldosterine
(62) have been previously published.

Plasma

epinephrine and

norepinephrine concentrations were determined by radioenzymatic assay (63) in the laboratory of Dr. Robert Sherwin.
Plasma glucose concentration was determined by the glucose
oxidase method (Glucose Analyzer, Beckman Instrument,
Fullerton, C.A.).

2
D.

Calculations
Creatinine clearance was calculated by the formula:

cGr

= UV/P

where U is the urinary creatinine concentration,

V is the

urine volume and P is the plasma creatinine concentration.
Urinary potassium excretion rate was calculated by
the formula:
K

exc

where Ug is the urinary potassium concentration,

V is the

urine volume and t is the time of urine collection in min¬
utes.

K

is expressed as >iEq/min.

The net amount of potassium excreted for any given
time period was calculated as the difference between the
mean rate of potassium excretion during the time period and
the mean baseline potassium excretion rate, times the time.
The net sodium excretion was calculated in a

similar

manner to that for net potassium excretion.
The amount of potassium that was translocated into
cells during any given time period was calculated from the
difference between the expected rise in plasma potassium
concentration and the actual rise in the plasma potassium
ccncentratio2i muitipled by the extracellular fluid volume
as follows:
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cellular uptake
of potassium
= (expected rise in Pv (mEq)
K
actual rise in P^.) x ECV
=

where
K

K •

n,

—

K

inf_exc
ECV

AP-K obs x ECV

is the total amount of potassium infused (mEq),
is the net amount of potassium excretion (mEq), APf/

,

is the net observed rise in plasma potassium concentration
(mEq/l) over the two hour potassium infusion and the subse¬
quent two hour measurement period, and ECV is the extracel¬
lular fluid volume calculated as 15% of body weight (liters)
The incremental area under the plasma potassium concen
tration-time curves was calculated using the trapezoidal rul
approximation and was carried out by the subroutine QA01AS
of the Harwell Subroutine Library of the Yale University I Eli
570/158 computer.

E.

It is expressed as mEq/l x min.

Statistical Analysis
Values are expressed as the mean i SEW.

Comparison

of groups was performed with the paired t-test (64).
regression was used for curve fitting.

Linear
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V.
A.

Results

Vital Signs
During the potassium chloride infusion alone, no

change in heart rate or blood pressure was observed.

When

epinephrine was infused with potassium chloride, a variable
increase in heart rate (15-20 beats per min) and a widening
of pulse pressure (10-20 mm Hg) occurred.

Subjectively,

most subjects reported feelings of tremulousness and a
pounding heart beat which was most marked at the beginning
of the epinephrine infusion and subsided after the first
sixty minutes.

When propranolol was added to the potassium

chloride and epinephrine infusion, no change in heart rate
or pulse pressure was observed and no subjective sensations
were reported by any volunteer.
B. Potassium
During the potassium chloride infusion alone baseline
plasma potassium concentration
a maximum of 0.83

-

(3*77

-

0.11 mEq/l) rose by

0.09 mEq/l (p <0.001)

(Figure 2).

This

maximum rise occurred at two hours into the study when the
potassium chloride infusion was stopped.

Thereafter, the

plasma potassium concentration progressively declined and
was 0.38
study.

-

0.14 mEq/l above basal values at the end of the

Urinary potassium excretion increased significantly

from a mean baseline rate of

37

-

12 pEq/min to a mean maxi-

imum rate of 184 ± 15 uEa/min (p < 0.001)

(Figure 3) without a

change in creatinine clearance (Figure 4).

47 1 4% of the

infused potassium -was excreted during the four hour study
period (Figure 5)«

Of the infused potassium that was

retained within the body at the end of the four hour study
period,
6).

24.8

1 1.17 mEq was translocated into cells (Figure

This represented 82

1 5% of the retained potassium

(Figure 7) and 43 ± 3% of the total amount of potassium admin¬
istered (Figure 8).

The incremental area in plasma potassium

during the 0-120 and 0-240 minute time periods was 65-3
and 126.5

-

16.2 mEq/1 x min respectively (Figure 9).

incremental area

-

5-8

The

in plasma potassium expressed per amount of

potassium retained during the same time periods was 1.5 - 0.2
and 4.2

1 0.5 min./l (Figure 10).

When epinephrine was infused alone for 30 minutes pre¬
ceding potassium chloride infusion, the plasma potassium con¬
centration fell from a baseline value of 3*66 i 0.10 mEq/1,
which was similar to that in the first study, to 0.61 ± 0.06
mEq/1 below baseline 30 minutes after beginning the epineph¬
rine infusion (p<0.00l)

(Figure ll).

When potassium chlor¬

ide infusion was added to the epinephrine infusion, the rise
in plasma potassium concentration was significantly less than
with potassium chloride infusion alone during the
minutes (p< 0.001)

(Figure 2).

first 120

During the last two hours fol¬

lowing potassium chloride administration, the

elevation of

the plasma potassium concentration above baseline was not
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statistically significantly different from that observed
with potassium chloride infusion alone.

Easeline urinary

excretion rate for potassium (U^V) was 37 - 7 jiEq/min and
was similar to that with potassium infusion alone (Figure 3)»
Following epinephrine infusion, however, U^V actually fell to
a mean value, 21 1 3 ^iFq/min, which was significantly below
the basal excretion rate (p<0.00l) and was markedly less
than the maximal excretion rate in the study with potassium
chloride infusion alone (p<O.QOl).
did not change during this study.

Creatinine clearance
The total potassium

excreted over the four hour study period fell below that
expected to result from continued basal rates of potassium
excretion (p<0.00i)

(Figure 5)«

Despite the marked decline

in Ugh/" the plasma potassium concentration actually rose less
in this study because the amount of potassium translocated
into cells increased by over 100%

in comparison to the

amount translocated with potassium chloride infusion alone
(p<0.00l)

(Figures 6 and 7)-

The incremental area in plasma

potassium was significantly less than with potassium chloride
infusion alone for all time periods (p^ 0.005)

(Figure 10).

When propranolol was infused with epinephrine for 30
minutes preceding potassium chloride infusion, the plasma
potassium concentration did not change significantly from
the baseline value of 3-69

-

0.11 mEq/1, which itself was

similar to the baseline plasma potassium concentrations in
the two previous studies.

When potassium chloride infusion

was added to the epinephrine and propranolol infusions,
the rise in plasma potassium concentration above baseline
was significantly greater than with potassium chloride
infusion alone during the first 120 minutes (p <0.01)
(Figure 2) and tended to remain high for the duration of
the study.

Ug-V (Figure

3) was significantly less during

the first 120 minutes of the study than in the study with
potassium infusion alone (p< 0.01) but was not different
during the remainder of the study.

Creatinine clearance

(Figure 4) was unaffected by the addition of propranolol.
The percentage of the potassium chloride dose excreted
(Figure 5) was 9 ± 2% at 120 minutes and 31 - 6% at 240
minutes with epinephrine and propranolol infusion and was
significantly less than with potassium infusion alone
(p<0.001 and p<0.02).

The absolute amount as well as the

percentage of the dose of potassium that was translocated
into cells tended to be increased with propranolol (Figures
6 and S) but did not reach statistical significance.
incremental area in plasma potassium (Figures

The

9 and 10) also

tended to be greater with the addition of propranolol to the
infusate.
During the potassium chloride infusion alone the
increase in the urinary potassium excretion rate correlated
linearly with the increase in plasma potassium concentration
over the time of the collection of each urine sample (Figure
12)

(r = 0.81, p <0.001).

Following the addition of
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epinephrine or epinephrine and propranolol to the infusate
no correlation between the change in PE and the change in
U-^V could be demonstrated.
C.

Sodium
Baseline plasma

sodium concentration was similar in

all three studies and was unaffected by potassium chloride,
epinephrine or propranolol infusion.

The baseline urinary

sodium excretion rate was also similar in all three studies
and rose following potassium chloride infusion (Figure

13)•

The rise with epinephrine and potassium chloride infusion,
however, was significantly less (p<0.02) than with potas¬
sium chloride infusion alone or with the addition of pro¬
pranolol to epinephrine and potassium.
D.

Glucose
Basting plasma glucose concentration was similar in the

potassium chloride (85-2

1 1.8 mg/dl), the potassium and

epinephrine (83-7 - 2.8 mg/dl),

and the potassium,

rine and propranolol (79-8 ± 2.8)

studies.

epineph¬

Plasma glucose

concentration remained unchanged during the potassium chlor¬
ide infusion.

When epinephrine was added to the infusate,

an immediate and significant rise in the plasma glucose con¬
centration occurred and the glucose concentration remained
elevated throughout the duration of the study (Pigure 14).
The plasma glucose concentration when propranolol was infused
with potassium chloride and epinephrine also rose significantly
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above the baseline value but remained significantly less
than the level in the potassium chloride and epinephrine
study (p< 0.001).
E.

Insulin
Baseline plasma insulin concentration was similar in

all three studies (Figure 15)•

No change in the insulin

concentration occurred following potassium chloride infusion
alone.

Epinephrine infusion resulted in a 15 to 20 ^lU/ml

increase in the plasma insulin concentration which correlated
temporally with the rise in plasma glucose concentration.
This rise in the insulin level persisted throughout the four
hour study period.

When propranolol was administered along

with epinephrine, an initial small decline in the plasma
insulin concentration was observed (Figure 15) but there¬
after the plasma

insulin values were not significantly dif¬

ferent from those in the potassium chloride infusion alone.
F.

Epinephrine and Norepinephrine
Baseline plasma

epinephrine and norepinephrine concen¬

trations during the potassium chloride infusion study alone
were 16.2

±

(Figurne 16).

8.0 pg/ml and 420.1

1 107.2 pg/ml respectively

Following infusion of potassium chloride, no

significant change in either catecholamine was observed.
G.

Aldosterone
Results pending.
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VI.

Discussion

The homeostatic mechanisms which control the net bal¬
ance and cellular distribution of potassium in living sys¬
tems are complex and interrelated.

This is necessary

because potassium plays a vital role in the function of all
cells, particularly in nerve and muscle tissue where elec¬
trical activity relies on the balance of intra- and extra¬
cellular potassium concentration.

The contributions of

insulin and aldosterone to internal and external potassium
balance have been elucidated in some detail and the impor¬
tance of each of these hormones in normal as well as abnor¬
mal states in controlling potassium homeostasis has been
recognized.

The present study indicates that epinephrine

and probably other sympathomimetic agents also play an
important role in both renal and extra-renal potassium
metabolism.
Previous studies in animals,

employing the infusion

of pharmacological doses of epinephrine and potassium have
demonstrated that epinephrine ameliorates the rise in plasma
potassium concentration and decreases the incidence of fatal
cardiac arrythmia

(2,49).

The present study extends these

earlier observations to man and documents that more physio¬
logic elevations in plasma

epinephrine levels,

similar to

those observed in stress (65), are capable of blunting the
rise in plasma potassium concentration following the infusion

■
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of small amounts of potassium.

In the present study,

each

subject received an infusion of epinephrine at the rate of
0.05

;ag/kg/min for

of potassium.

30

minutes prior to the administration

During this period, the plasma potassium

concentration declined by 0.42 ± 0.05 mEq/1 during the first
15 minutes and by 0.61

1

0.06 mEq/1 by 30 minutes.

This

decline could not be accounted for by an increase in plasma
insulin concentration;

insulin remained unchanged at 15

minutes and was only slightly elevated at 30 minutes.

Three

of six subjects showed no rise in plasma insulin concentra¬
tion during the first
yet demonstrated a
concentration.

30

minutes post epinephrine infusion

significant decline in plasma potassium

When potassium was administered following

pretreatment with epinephrine, the rise in plasma potassium
concentration during the first two hours was significantly
attenuated.

This blunted rise in plasma potassium concen¬

tration is even more striking when changes in urinary potas¬
sium excretion are taken into account.

Eollowing potassium

chloride infusion alone, 47% of the infused potassium was
excreted.

This value agrees well with those previously

reported under similar experimental conditions (66).

When

epinephrine was infused along with potassium chloride urin¬
ary potassium excretion was markedly inhibited and actually
fell below baseline values (p< 0.001).

When the rise in

plasma potassium concentration is viewed in the context of
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the amount of infused potassium which is retained within
the body, a greater than 100% increase in the amount of
potassium translocated into cells was observed (Figures 6
and 10).

The importance of this protective effect of epi¬

nephrine on potassium tolerance would assume particular sig¬
nificance during conditions of stress.

Under such circum¬

stances, protein breakdown is accelerated and a state of
net catabolism exists.

This would be expected to result in

a net efflux of potassium from the intracellular to the
extracellular compartment at a time when both insulin secre¬
tion (56,67) and insulin action (68) are significantly
impaired.

Since stress is known to stimulate epinephrine

release, the increased circulating levels of this hormone
could exert a protective effect against the development of
hyperkalemia.
The sites of the stimulatory effect of epinephrine on
cellular uptake of potassium are not discernible in the pres¬
ent study.

Previous work, however, suggests that both the

liver and skeletal muscle are quantitatively the most impor¬
tant tissues that participate in epinephrine-mediated potas¬
sium disposal.

The mechanism by which epinephrine augments

cellular uptake of potassium is most likely related to stim¬
ulation of beta adrenergic receptors since the augmentation
can be blocked by propranolol.

Recent studies have demon¬

strated the presence of beta receptors on both liver and
skeletal muscle cells (69,70).

In spite of this, an indirect

effect of epinephrine, mediated via
or aldosterone secretion
study.

stimulation of insulin

cannot he excluded by the present

The latter would seem unlikely, however,

since the

effect of epinephrine on potassium is immediate while the
increase in plasma aldosterone does not occur until

30 to

60 minutes (71) following epinephrine administration, and
the onset of action of aldosterone in stimulating potassium
transport in the kidney is delayed by an additional 60 to
120 minutes (72).

That part of the effect of epinephrine on

enhancing potassium uptake is mediated via insulin cannot be
excluded.

Although the initial decline in plasma potassium

concentration during the first

30 minutes of epinephrine

infusion prior to potassium infusion

cannot

be explained by

stimulation of insulin secretion, the blunted rise in plasma
potassium concentration during potassium chloride infusion
could be explained in part by release of insulin secondary
to the epinephrine-induced hyperglycemia.

Previous studies,

employing much higher doses of epinephrine have demonstrated
a complete inhibition of insulin secretion despite the pres¬
ence of hyperglycemia

(53-56).

In the present study,

ing much lower doses of epinephrine,

employ¬

it is likely that the

beta adrenergic inhibitory effect of epinephrine on insulin
secretion was insufficient to completely block the effect of
hyperkalemia on the pancreatic beta cell,

and the alpha

adrenergic stimulatory effect of epinephrine on insulin
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secretion predominated.

In any event,

it is clear that in

terms of potassium metabolism, an intermediary role for
insulin cannot be ruled out in this study.

Infusion of

insulin to levels similar to those observed in response to
epinephrine infusion in the present study have been shown
to result in increased cellular uptake of potassium and a
fall in plasma potassium concentration (12).

However, the

magnitude of this fall was significantly less than that
observed in the present study with epinephrine infusion
leaving open the possibility of a direct role for epineph¬
rine in ameliorating the rise in plasma potassium following
potassium infusion.
evaluate what role,

Studies are presently in progress to
if any,

mediated hypokalemic effect.

insulin plays in the epinephrineIn these studies,

somatostatin

is infused to inhibit insulin secretion and basal insulin
levels are replaced with an exogenous infusion of insulin.
The same infusion of potassium chloride and epinephrine will
then be administered while plasma insulin levels are main¬
tained at basal.

Any observed hypokalemic effect would then

be attributable to epinephrine alone.
The effect of epinephrine on potassium tolerance can¬
not be explained by enhanced renal excretion of potassium
since this excretion is decreased markedly following epi¬
nephrine infusion.

This anti-kaluretic effect cannot be

explained by a fall in the peritubular capillary potassium
concentration perfusing the distal nephron or by a fall in
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the filtered load of potassium since the plasma potassium
concentration increased following potassium chloride infu¬
sion and the glomerular filtration rate was unchanged.

Epi¬

nephrine is known to decrease renal plasma flow (30,51)*
however, and it is possible that the total amount of potas¬
sium presented to the distal potassium secretory sites
actually diminished,
excretion rate,
tion rose.

leading to a decrease in the potassium

even though the plasma potassium concentra¬

Alternatively, a direct inhibitory effect of epi¬

nephrine on peritubular potassium uptake is possible.
seems unlikely, though,

This

since one would have to postulate

that the renal tubular cell is different from other cells
where epinephrine stimulates potassium uptake (7-10).
Following epinephrine infusion, the rise in urinary
sodium excretion was not as great as with potassium infu¬
sion alone (Figure 13)•

Although this relative decrease

(compared with potassium chloride alone)

in sodium excre¬

tion could explain a blunted rise in renal potassium excre¬
tion,

it cannot explain the absolute decrease in potassium

excretion that was actually observed.
Since epinephrine is known to increase aldosterone
secretion (57)

(results from present study pending) over a

prolonged time course and insulin has no known effect on
renal potassium handling (23),

it is unlikely that changes

in the circulating levels of these hormones would effect
renal potassium excretion in the present study.
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The infusion of propranolol in conjunction with epi¬
nephrine and potassium chloride reverse almost completely
the renal and extra-rena1-effects of epinephrine indicating
that the effect of epinephrine on potassium metabolism is
mediated by stimulation of beta adrenergic receptors.

The

addition of propranolol effectively blocked the inital fall
in plasma potassium concentration observed with epinephrine
infusion alone, and prevented the protective effect of epi¬
nephrine on potassium tolerance.

In fact, the rise in plasma

potassium concentration when propranolol was infused with
epinephrine and potassium chloride was actually greater than
with potassium chloride alone.

Renal excretion was returned
/

almost to normal by propranolol but the rate was still less
than with potassium infusion alone indicating that the pro¬
pranolol was not completely blocking the effects of epineph¬
rine on potassium excretion at the doses of the two drugs
used.

Propranolol also markedly decreaseed cellular uptake

of potassium that would have proceeded under the influence
of epinephrine alone (figures 6 and 7)»
The deleterious effects of propranolol on potassium
tolerance could be explained in several ways,

first,

it is

possible that during the potassium chloride infusion alone
the rise in plasma potassium concentration stimulates epi¬
nephrine release from the adrenal medulla

or leads to local

56
release of epinephrine at sympathetic nerve terminals inervating liver and skeletal muscle cells (73)»

Propranolol,

hy blocking this stimulatory effect of' potassium,
a detrimental effect on potassium tolerance.

could have

Preliminary

measurements of circulating catecholamines during the potas¬
sium chloride infusion, however, fail to demonstrate a
sistent increase in circulating plasma
(Figure 16).

con¬

epinephrine levels

However, this could not exclude the possibility

that a rising plasma potassium concentration could activate
sympathetic nerve fibers innervating muscle and liver cells
with local uptake and degradation of epinephrine.

Such local

epinephrine metabolism has been shown to occur by Axelrod
(75)•

It is also possible that basal levels of epinephrine

or sympathetic nervous activity are necessary to dispose of
an exogenous potassium load normally and that propranolol,
by inhibiting basal epinephrine release or sympathetic ner¬
vous system activity,

leads to impaired potassium tolerance.

This would be similar to the situation with insulin where
inhibition of basal insulin secretion by as little as

50%

results in a marked impairment in potassium tolerance.

Fur¬

ther studies are now in progress with potassium chloride and
propranolol infusion alone to investigate this question.
The results in the present study also exclude a direct
effect of propranolol mediated by mechanisms other than
inhibition of beta adrenergic receptors stimulation.
propranolol was infused with epinephrine,

When

insulin levels
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fell slightly (2 to 5 jiU/ml).

This decrease was not signifi¬

cantly different from control after the first 15 minutes of
potassium chloride infusion and in 3 of 6 subjects no decrease
at all in plasma

insulin concentration was observed.

These

results make it unlikely that the decrement in potassium
tolerance can be explained by inhibition of insulin release.
Likewise, the time course of the inhibitory effect of pro¬
pranolol on aldosterone secretion would be too long to explain
the present results.

Measurement of plasma aldosterone con¬

centrations are pending and will directly answer this ques¬
tion.

If it indeed becomes clear that basal sympathetic

activity is important in potassium tolerance and homeostasis
in general it would raise the question of whether potassium
tolerance is compromised in states of functional sympathect¬
omy such as diabetic neuropathy or propranolol use for ische¬
mic heart disease.
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VII.

Summary

In summary, the present study documents that physio¬
logic elevations of circulating plasma

epinephrine concen¬

trations ameliorate the rise in plasma potassium concentra¬
tion following a potassium chloride infusion.

This effect

is the result of enhanced cellular uptake of potassium and
can he completely reversed hy propranolol,

indicating that

epinephrine's protective effect on potassium tolerance is
mediated via

stimulation of "beta adrenergic receptors.
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Table I.

Subject Profile

Age

Height
(cm)

Weight
(kg)

Subject

(yrs.)

Sex

1

22

M

188

76

2

21

M

186

82

3

IS

M

192

96

4

20

1

160

65

5

18

M

172

71

6

18

M

186

76
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CREATININE CLEARANCE
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FIGURE 7.

% of Total Potassium Dose Excreted
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FIGURE 11
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FIGURE 13

NET URINARY SODIUM EXCRETION RATE
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